Skip to main content
. Author manuscript; available in PMC: 2019 Mar 22.
Published in final edited form as: Nat Med. 2012 Feb 12;18(3):375–377. doi: 10.1038/nm.2644

Table 1.

Characteristics of lung adenocarcinomas with the KIF5B-RET fusion

Sample Country Sex Agea Smoking KIF5B-RET fusionb Pathological stage Pathological findings RET staining TTF-1 staining Napsin A staining Thyrogloblin staining
BR0020 Japan Male 57 Never K15; R12 (variant 1) IIB Moderately differentiated ADC + + + −
BR1001 Japan Female 65 Never K15; R12 (variant 1) IB Well differentiated ADC + + + −
BR1002 Japan Female 64 Never K15; R12 (variant 1) IB Well differentiated ADC + + + −
BR0030 Japan Male 57 Never K16; R12 (variant 2) IA Well differentiated ADC + + + −
BR1003 Japan Male 28 Never K23; R12 (variant 3) IA Well differentiated ADC + + + −
BR1004 Japan Female 71 Never K24; R8 (variant 4) IA Moderately differentiated ADC NT NT NT NT
NCI1580 USA Male 63 Everc K15; R12 (variant 1) II Moderately differentiated ADC NT NT NT NT
a

Age in years.

b

Fused exon numbers of KIF5B (K) and RET (R); and variant types (in parentheses) are shown. None of the subjects had oncogenic EGFR, KRAS, HER2 or ALK mutations or fusions.

c

The number of pack years smoked for this subject is not known. NT, not tested.